Relypsa, Sanofi in starting gate for patiromer launch, with FDA decision imminent

Relypsa ($RLYP) and Sanofi ($SNY) are raring to go for a prospective launch of patiromer, a treatment for hyperkalemia. And they need to get going, considering a competitor med might hit the market in mid-2016. All they need is an FDA approval, and that yea-or-nay decision is expected today. More from FiercePharmaMarketing